Breaking Down Raysum Co., Ltd. Financial Health: Key Insights for Investors

Curious whether Raysum Co., Ltd. (8890.T) is a value play or a cautionary tale? This deep-dive teases out sharp contrasts: fiscal-year revenue of ¥94.3 billion (up 4.7% YoY, with TTM revenue at ¥96.87 billion), a solid profit margin of 8.17% and ROE of 13.33% alongside an operating margin of 17.25% and EBITDA margin of 17.80%, yet the company grapples with a heavy capital structure-total debt of ¥97.61 billion (debt/equity 1.60) and negative operating cash flow of ¥41.74 billion and free cash flow of ¥41.92 billion-while market participants value the firm at a capitalization of ¥169.32 billion (P/E 21.37, P/S 1.75, P/B 2.77, EV/EBITDA 14.24), a trailing EPS of ¥275.60, book value per share of ¥2,122.57, an Altman Z-Score of 2.93, and a striking +180.8% total shareholder return over the last year; read on to see how revenue per employee (~¥452.65 million), a negative TTM cash flow, liquidity ratios (current 11.84, quick 1.80), and segment exposure to real estate and healthcare could influence the risk/reward calculus for investors.

Raysum Co., Ltd. (8890.T) - Revenue Analysis

• FY ending March 31, 2024 revenue: ¥94.3 billion (up 4.7% year-over-year)
• FY ending March 31, 2023 revenue: rose 38.82% versus prior year
• Quarter ending December 31, 2024 revenue: ¥7.69 billion (down 46.67% year-over-year)
• Trailing twelve months (TTM) revenue: ¥96.87 billion (down 0.95% year-over-year)
• Revenue per employee: ~¥452.65 million
• Market capitalization: ¥169.32 billion; Price-to-Sales (P/S) ratio: 1.75

Raysum Co., Ltd. (8890.T) - Profitability Metrics

Raysum Co., Ltd. (8890.T) shows a solid profitability profile across margins and returns, driven by robust operating performance and efficient use of equity. Below are the primary metrics for investors to consider.

• Net income (TTM): ¥7.92 billion - profit margin: 8.17%
• Operating income (FY ending Mar 31, 2024): ¥16.71 billion - operating margin: 17.25%
• Gross margin: 25.84%
• EBITDA margin: 17.80%
• Return on equity (ROE): 13.33%
• Earnings per share (EPS, TTM): ¥275.60 - trailing P/E: 21.37

• Margins profile: Gross 25.84% → Operating 17.25% → Net 8.17% - indicates meaningful operating leverage but notable non-operating/after-tax impacts.
• Cash profitability (EBITDA margin 17.80%) aligns closely with operating margin, suggesting limited non-cash distortions.
• ROE of 13.33% with EPS ¥275.60 and P/E 21.37 positions valuation relative to earnings generation for equity holders.

For context on corporate direction and how profitability ties into strategic priorities, see: Mission Statement, Vision, & Core Values (2026) of Raysum Co., Ltd.

Raysum Co., Ltd. (8890.T) - Debt vs. Equity Structure

• Total debt: ¥97.61 billion (FY ending March 31, 2024)
• Debt-to-equity ratio: 1.60
• Equity ratio: 47.8%
• Net cash position: -¥76.21 billion (debt exceeds cash & equivalents)
• Interest coverage ratio: 14.92
• Book value per share: ¥2,122.57
• Price-to-book (P/B) ratio: 2.77
• Enterprise value: ¥245.58 billion

• Leverage profile: Debt-to-equity of 1.60 and negative net cash (-¥76.21B) denote meaningful leverage but not excessive given interest coverage of 14.92.
• Solvency context: Equity ratio of 47.8% signals nearly balanced financing between debt and equity, cushioning creditors and shareholders.
• Investor valuation: Book value per share of ¥2,122.57 vs. P/B 2.77 implies market capitalization places a premium over accounting equity; enterprise value ¥245.58B reflects debt-adjusted valuation.
• Operational buffer: Interest coverage near 15× suggests operating earnings comfortably cover interest expense, lowering short-term default risk despite net indebtedness.

Raysum Co., Ltd. (8890.T) - Liquidity and Solvency

• Current ratio: 11.84 - very strong short-term liquidity (current assets >> current liabilities).
• Quick ratio: 1.80 - sufficient immediately liquid assets to meet near-term obligations.
• Operating cash flow (TTM): ¥-41.74 billion - operations are consuming cash.
• Free cash flow (TTM): ¥-41.92 billion - capex exceeds cash generated by operations.
• Net debt: ¥250.13 million vs. Total assets: ¥885.16 million - modest absolute leverage relative to asset base.
• Beta: -0.13 - low/negative correlation with market movements; potentially defensive behavior.

• High current ratio is a liquidity strength but large negative operating and free cash flows signal operational cash stress that merits monitoring.
• Net debt is small in absolute terms relative to assets, but persistent negative cash flow can erode liquidity over time.
• Negative beta indicates portfolio diversification potential versus broader equity moves.

Raysum Co., Ltd. (8890.T) - Valuation Analysis

• Market capitalization: ¥169.32 billion
• Enterprise value (EV): ¥245.58 billion
• P/E ratio (trailing): 21.37 - indicates moderate growth expectations; forward P/E not available
• P/B ratio: 2.77 - stock trading above book value
• EV/EBITDA: 14.24 - valuation relative to operating cash earnings
• P/S ratio: 1.75 - moderate multiple on sales

• Relative context: a P/E ~21 and EV/EBITDA ~14 suggest investors pay for steady profitability but not at aggressive growth premiums.
• Premium P/B (2.77) implies expectations of returns or intangibles not reflected on the balance sheet.
• EV substantially higher than market cap (¥245.58B vs. ¥169.32B) indicates material net debt or other non-equity claims included in EV.

Raysum Co., Ltd. (8890.T) - Risk Factors

• Operating cash flow: ¥-41.74 billion - persistent negative operating cash flow signals challenges in converting revenue into cash and sustaining day-to-day operations from core activities.
• Free cash flow: ¥-41.92 billion - negative free cash flow indicates capital expenditures exceed cash generated by operations, constraining capacity to invest without external financing.
• Net debt: ¥250.13 million vs. Total assets: ¥885.16 million - while net debt in absolute terms is modest, relative to total assets it implies leverage that reduces balance-sheet flexibility.
• Debt-to-equity ratio: 1.60 - a higher reliance on debt financing increases interest and refinancing risk, particularly if operating cash generation remains weak.
• Altman Z-Score: 2.93 - a score below 3.0 is commonly interpreted as elevated financial distress risk and a warning signal for potential bankruptcy pressures.
• Beta: -0.13 - a negative beta reflects low or inverse correlation with the broader market; this can reduce market-driven upside during rallies but may also limit diversification benefits and complicate valuation models.

• Liquidity shock: continued negative operating cash flow could force asset sales or expensive debt raises, amplifying dilution or solvency pressure.
• Refinancing risk: with debt-to-equity at 1.60 and negative free cash flow, upcoming maturities may require market access at unfavorable terms.
• Operational deterioration: persistent cash burn suggests either margin compression, working-capital stress, or inadequate pricing/volume - each requiring corrective management action.
• Market-behavior mismatch: negative beta means the stock may not hedge typical market moves; event-driven or idiosyncratic risks may dominate price action.

Raysum Co., Ltd. (8890.T) - Growth Opportunities

• Revenue growth: +38.82% (FY ended March 31, 2023), signaling accelerated organic expansion and successful asset deployment.
• Market capitalization: ¥169.32 billion; Enterprise value: ¥245.58 billion - indicating available market value relative to invested capital and potential upside from portfolio revaluation or earnings expansion.
• Equity ratio: 47.8% - a solid capital structure that supports further investment, acquisitions, and development without excessive leverage.
• Total shareholder return (1 year): +180.8% - strong investor confidence and momentum that can facilitate capital access for growth initiatives.

• Healthcare & medical facilities: demand-driven by Japan's aging demographics and rising need for elderly-care infrastructure.
• Retail buildings & offices: selective exposure providing income diversification and opportunities for rental yield improvement in high-demand locations.
• Development & asset management: potential to enhance returns via redevelopment, upgrading medical-grade properties, and leasing optimization.